Abstract
Chronic Obstructive Pulmonary Disease (COPD), being a major cause of morbidity and mortality worldwide, is a major problem for public health. It is predicted that its burden will continuously expand over the next years. This article is an up-to-date review of both non-pharmacologic and pharmacologic management of COPD, which is now based on new staging systems, able to predict prognosis and the response to different treatment approaches. Non-pharmacologic therapies, such as smoking cessation, vaccinations and pulmonary rehabilitation are covered briefly. Current pharmacologic management covers short acting beta-agonists (SABA), short acting muscarinic antagonists (SAMA), long acting beta agonists (LABA), long acting antimuscarinics (LAMA), inhaled corticosteroids (ICS), LABA/ICS combinations, xanthines, specific phosphodiesterase 4 (PDE4) inhibitors and oxygen therapy.
Keywords: Chronic obstructive pulmonary disease (COPD), disease management, pharmacotherapy, phenotypes, rehabilitation.
Current Respiratory Medicine Reviews
Title:Management of Stable COPD: An Update
Volume: 9 Issue: 6
Author(s): Alexandru Corlateanu, Gloria Montanari, Alexandros G. Mathioudakis, Victor Botnaru and Nikolaos Siafakas
Affiliation:
Keywords: Chronic obstructive pulmonary disease (COPD), disease management, pharmacotherapy, phenotypes, rehabilitation.
Abstract: Chronic Obstructive Pulmonary Disease (COPD), being a major cause of morbidity and mortality worldwide, is a major problem for public health. It is predicted that its burden will continuously expand over the next years. This article is an up-to-date review of both non-pharmacologic and pharmacologic management of COPD, which is now based on new staging systems, able to predict prognosis and the response to different treatment approaches. Non-pharmacologic therapies, such as smoking cessation, vaccinations and pulmonary rehabilitation are covered briefly. Current pharmacologic management covers short acting beta-agonists (SABA), short acting muscarinic antagonists (SAMA), long acting beta agonists (LABA), long acting antimuscarinics (LAMA), inhaled corticosteroids (ICS), LABA/ICS combinations, xanthines, specific phosphodiesterase 4 (PDE4) inhibitors and oxygen therapy.
Export Options
About this article
Cite this article as:
Corlateanu Alexandru, Montanari Gloria, G. Mathioudakis Alexandros, Botnaru Victor and Siafakas Nikolaos, Management of Stable COPD: An Update, Current Respiratory Medicine Reviews 2013; 9 (6) . https://dx.doi.org/10.2174/1573398X10666140222001646
DOI https://dx.doi.org/10.2174/1573398X10666140222001646 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Autism - A Comprehensive Array of Prominent Signs and Symptoms
Current Pharmaceutical Design Gene Expression Signatures in Primary Immunodeficiencies: The Experience from Human Disease and Mouse Models
Current Molecular Medicine Diabetes NEP-Like Endopeptidases and Alzheimers Disease
Current Alzheimer Research Graphical Abstracts:
Central Nervous System Agents in Medicinal Chemistry The Clinical Utility of Ambulatory Blood Pressure Monitoring (ABPM): A Review
Current Hypertension Reviews Myocardial Protection Against Ischemia-Reperfusion Injury: Novel Approaches in Maintaining Homeostatic Stability in Blood
Recent Patents on Cardiovascular Drug Discovery Current and Future Applications for Stem Cell Therapies in Spine Surgery
Current Stem Cell Research & Therapy Neonatal Formulations: The Need for a Tailored, Knowledge Driven Approach
Current Pharmaceutical Design An Overview on COVID-19 and its Effect on Cardiovascular Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Emerging Use of Nanotechnology in the Treatment of Neurological Disorders
Current Pharmaceutical Design Histone Deacetylase Inhibitors and Colorectal Cancer: what is new?
Anti-Cancer Agents in Medicinal Chemistry Early Biomarkers for Severe Drug Hypersensitivity Reactions
Current Pharmaceutical Design Novel Biomarkers for Lupus Nephritis in the “OMICS” Era
Current Medicinal Chemistry Vasoactive Intestinal Peptide in Neurodevelopmental Disorders:Therapeutic Potential
Current Pharmaceutical Design Novel Drugs for Chronic Lymphoid Leukemias: Mechanism of Action and Therapeutic Activity
Current Medicinal Chemistry Molecular Targeting Agents in Renal Cell Carcinoma: Present Strategies and Future Perspectives
Current Pharmaceutical Design Clinical Trajectories and Biological Features of Primary Progressive Aphasia (PPA)
Current Alzheimer Research Targeting Matrix Metalloproteinases in Acute Inflammatory Shock Syndromes
Combinatorial Chemistry & High Throughput Screening Kainate Receptors and Pain: From Dorsal Root Ganglion to the Anterior Cingulate Cortex
Current Pharmaceutical Design Substance P and Alzheimer’s Disease: Emerging Novel Roles
Current Alzheimer Research